Table 1.
Demographic and clinical characteristics of CRC patients participating in this study
| Variable | Chemotherapy (n = 13) | No chemotherapy (n = 8) |
|---|---|---|
| Demographic attributes | ||
| Female gender, n (%) | 6 (46) | 4 (50) |
| Mean age, years (±SD) | 54 ± 9 | 74 ± 5 |
| Median age, years (range) | 55 (40–64) | 73 (71–80) |
| Male gender, n (%) | 7 (54) | 4 (50) |
| Mean age, years (±SD) | 59 ± 10 | 62 ± 13 |
| Median age, years (range) | 63 (46–70) | 62 (47–77) |
| Body mass index, Mean ± SD | 25 ± 5 | 27 ± 4 |
| Oncological attributes | ||
| Type of primary cancer, n (%) | ||
| Colon | 10 (77) | 6 (75) |
| Rectum | 3 (23) | 2 (25) |
| CEA, median level in ng/mL (range) | 28.3 (1–4220) | 10 (8–49) |
| Synchronous metastases, n (%) | 12 (92) | 4 (50) |
| Median number of lesions, n (range) | 3 (2–9) | 2 (1–3) |
| Chemotherapy | ||
| FOLFOX, n (%) | 8 (62) | N/A |
| FOLFOX + Avastin, n (%) | 5 (38) | N/A |
| Surgical attributes | ||
| ASAa fitness category, n (%) | ||
| <3 | 6 (46) | 1 (12) |
| 3 | 7 (54) | 7 (82) |
| ≥4 | 0 (0) | 0 (0) |
| Simultaneous resection, n (%) | 1 (8) | 2 (25) |
| Complicationsb, n (%) | ||
| Minor (≤grade III) | 4 (31) | 2 (25) |
| Major (grade IIIa) | 2 (15) | 0 (0) |
| Severe (≥grade IIIb) | 2 (15) | 0 (0) |
| Clinical outcomes | ||
| Median length of hospital stay (days) | 7 | 9 |
| 90-day mortality, n (%) | 0 (0) | 0 (0)c |
| Recurrenced, n (%) | 1 (8) | 1 (20) |
CEA carcinoembryonic antigen, N/A not applicable
a According to American Society of Anesthesiologists (ASA) physical status classification (https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system)
b According to the Clavien–Dindo classification
c Zero for five patients and data not available yet for the remaining three patients
d Local, regional and/or distal recurrence